Urgent

Acute graft-versus-host disease

Transplant complication · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Donor immune cells attacking recipient tissues after allogeneic stem-cell transplant, classically affecting skin (rash), gut (diarrhoea) and liver (cholestasis). Usually within the first weeks to 100 days.

Red flags

  • High-volume/bloody diarrhoea and ileus
  • Rapidly rising bilirubin
  • Extensive/bullous skin involvement
  • Concurrent infection/sepsis

Assessment

Differential diagnosis

  • Drug reaction/DRESS
  • Infectious enteritis (CMV, C. difficile)
  • Viral hepatitis / drug hepatotoxicity
  • Engraftment syndrome
  • Sepsis

Investigations

  • Clinical staging of skin, gut and liver involvement
  • LFTs, U&E, FBC
  • Stool studies (exclude infection, especially CMV and C. difficile)
  • Skin/gut biopsy to confirm; CMV monitoring

Management

  • Confirm diagnosis and exclude infection mimics (biopsy where possible)
  • Continue calcineurin inhibitor prophylaxis and optimise levels
  • Start systemic corticosteroids as first-line treatment for significant (grade >=II) disease
  • Supportive care - fluids, nutrition, skin care, gut rest
  • Involve the transplant team; escalate to second-line immunosuppression (e.g. ruxolitinib) for steroid-refractory disease

Drugs & doses

Systemic corticosteroids (first line)
Calcineurin inhibitor (ciclosporin/tacrolimus) continuation
Ruxolitinib for steroid-refractory acute GVHD
Topical steroids for limited skin disease; supportive/antimicrobial cover

Disposition

Admit under/with the transplant haematology team; ICU/HDU for severe multi-organ disease.

Complications & pitfalls

  • Severe fluid/electrolyte loss and malnutrition
  • Life-threatening infection from immunosuppression
  • Progression to chronic GVHD
  • Death

Exam pearls

  • Exclude infection (CMV, C. difficile) which mimics and coexists with gut GVHD.
  • Steroid-refractory GVHD carries a poor prognosis - escalate promptly with the transplant team (ruxolitinib is a recognised option).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.